Какова цена за MGC Pharmaceuticals Limited (MXC)

Цена за MGC Pharmaceuticals Limited (MXC) Это $0.27239819

Какова рыночная капитализация для MGC Pharmaceuticals Limited (MXC)

Рыночная капитализация для MGC Pharmaceuticals Limited (MXC) Это $330.42K

Прибыль MGC Pharmaceuticals Limited (MXC)

MGC Pharmaceuticals Limited, an Australian biopharmaceutical firm established in West Perth in 2014, focuses on the worldwide development and distribution of plant-derived medicines. Its product portfolio encompasses both medicinal cannabis solutions and other botanical therapeutics. The company's key investigational treatments include CimetrA, currently in Phase III clinical trials for the symptomatic relief of early-stage COVID-19; CannEpil, a cannabis-based therapy undergoing Phase IIb studies for drug-resistant epilepsy; and CogniCann, which is in Phase II clinical development for alleviating dementia symptoms. Beyond these core candidates, MGC Pharmaceuticals also supplies the ArtemiC range, various other cannabinoid-infused products, and non-pharmaceutical items. Additionally, the company provides expert consulting services, particularly in clinical research. The company was previously named Erin Resources Limited before adopting its current identity, MGC Pharmaceuticals Limited, in December 2015.

Год	Прибыль	Изменить
Недостаточно данных для указанных дат.

Год

Прибыль

Изменить

Недостаточно данных для указанных дат.

Компания	Прибыль	Разница в прибыли	Страна
MERCK Kommanditgesellschaft auf Aktien MER.SW	-	-	DE
Merck KGaA MRK.DE	-	-	DE
Takeda Pharmaceutical Company Limited 4502.T	-	-	JP
Galderma Group AG GALD.SW	-	-	CH
Sun Pharmaceutical Industries Limited SUNPHARMA.NS	$1.76B	-	IN

Компания

Прибыль

Разница в прибыли

Страна